- In September 2021, GE Healthcare announced its agreement to acquire BK Medical from Altaris Capital Partners, LLC, for USD 1.45 billion in cash. This acquisition marked a strategic expansion of GE Healthcare's ultrasound business, integrating BK Medical's expertise in real-time surgical visualization with GE's pre- and post-operative imaging capabilities. The move aimed to create an end-to-end solution across the continuum of care, from diagnosis to therapy and beyond. BK Medical's advanced technologies, particularly in intraoperative imaging and surgical navigation, complemented GE Healthcare's portfolio, enhancing its ability to support clinicians in making critical decisions during surgeries. This acquisition underscored GE Healthcare's commitment to innovation and its focus on delivering precision healthcare solutions
- In March 2023, Waters Corporation unveiled the Alliance iS, a cutting-edge High-Performance Liquid Chromatography (HPLC) system designed to elevate efficiency and precision in chromatography applications, including protein purification. This next-generation system incorporates advanced features such as proactive error detection, guided troubleshooting, and an intuitive touchscreen interface, significantly reducing common laboratory errors by up to 40%. Tailored for biopharmaceutical and research applications, the Alliance iS streamlines workflows, enhances compliance, and ensures reliable analytical processes. Its integration with Waters' Empower Chromatography Software and eConnect HPLC Columns further optimizes operational risk management and productivity1. This innovation underscores Waters Corporation's commitment to addressing the evolving needs of modern laboratories
- In March 2023, Thermo Fisher Scientific and Symphogen extended their collaboration to advance biopharmaceutical research and development by offering streamlined platform workflows. This partnership emphasizes the development of tools for quality monitoring and simplified characterization of complex therapeutic proteins, addressing the growing need for precision and efficiency in the biopharmaceutical industry. By integrating advanced analytical technologies, such as mass spectrometry and chromatography, the collaboration aims to enhance the analysis of monoclonal antibody mixtures and other complex protein therapeutics. This initiative reflects a shared commitment to innovation, supporting researchers in accelerating drug discovery and development processes
